In today’s session Sarepta Therapeutics Inc (SRPT) registered an unusually high (574) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious SRPT increase. With 574 contracts traded and 12774 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: SRPT161118C00039000 closed last at: $0.15 or 78.6% down. About 201,751 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 90.92% since April 20, 2016 and is uptrending. It has outperformed by 86.36% the S&P500.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Piper Jaffray given on Monday, January 18. The rating was upgraded by PiperJaffray to “Overweight” on Monday, September 19. The stock has “Market Perform” rating given by William Blair on Thursday, April 21. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Buy” rating given on Friday, October 2 by Needham. The rating was downgraded by Oppenheimer on Tuesday, April 26 to “Perform”. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Neutral” rating by Janney Capital on Wednesday, April 20. RBC Capital Markets maintained the shares of SRPT in a report on Friday, October 28 with “Outperform” rating. The stock has “Buy” rating given by Robert W. Baird on Thursday, August 27. Wedbush maintained the shares of SRPT in a report on Wednesday, July 20 with “Outperform” rating. The rating was maintained by Cowen & Co on Wednesday, August 26 with “Hold”.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.52 in 2016 Q2. Its up 0.36, from 1.16 in 2016Q1. The ratio improved, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Blackrock Grp Inc Ltd owns 77,227 shares or 0% of their US portfolio. Group Inc One Trading Lp last reported 571,145 shares in the company. Jefferies Grp last reported 685,629 shares in the company. Mycio Wealth Ltd Company accumulated 0% or 700 shares. Schwab Charles Invest Mngmt holds 153,816 shares or 0% of its portfolio. Guggenheim Ltd has 0.01% invested in the company for 123,869 shares. Parametric Port Limited holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 136,273 shares. Advisory Service Net Limited Liability holds 0% or 455 shares in its portfolio. Tower Rech Capital Limited Liability Company (Trc) reported 1,117 shares or 0% of all its holdings. Ameriprise accumulated 0% or 56,887 shares. Raymond James And reported 15,151 shares or 0% of all its holdings. Ladenburg Thalmann Fin holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 4,892 shares. Ghost Tree Cap Ltd Liability has 1.1% invested in the company for 200,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 1,063 shares. Jpmorgan Chase And holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 570 shares.
Insider Transactions: Since September 14, 2016, the stock had 0 buys, and 8 selling transactions for $8.94 million net activity. Another trade for 24,352 shares valued at $1.22M was made by Kaye Edward M. MD on Monday, September 19. $438,660 worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares were sold by Ruff Shamim. On Monday, September 19 Aphale Jayant sold $1.75M worth of the stock or 35,000 shares. Howton David T also sold $420,000 worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) on Thursday, September 22. Shares for $1.50 million were sold by Mahatme Sandesh.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $2.06 billion. The Firm is focused on the discovery and development of ribonucleic acid -targeted therapeutics for the treatment of rare, infectious and other diseases. It currently has negative earnings. The Firm operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.